Indian Pharma Industry Outlook 2025: Market Trends and Stock Performance Part 3

Challenges to Consider Potential U.S. Tariffs on Indian Pharma Imports The U.S. administration has proposed a 25% tariff on drug imports, which may impact exports. Source: Reuters Pricing Pressure and Regulatory Challenges Generic drugmakers in the U.S. face FDA approval delays, pricing pressures, and increasing inspections. Source: Reuters Conclusion The Indian pharmaceutical sector is expected to see strong growth in 2025, driven by domestic demand, exports, and government policies. Pharma stocks are likely to perform well, but investors must be mindful of global trade policies and regulatory hurdles.